Business Context and Reporting Period
Company: Collegium Pharmaceutical, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 26, 2016
Event: Entry into a Material Definitive Agreement for an underwritten public offering of common stock.
Key Financial Metrics
This filing details a capital raise rather than operational financial performance. Key metrics related to the transaction include:
- Shares Issued (Firm Commitment): 5,000,000 shares of common stock.
- Public Offering Price: $16.00 per share.
- Price to Underwriters: $15.04 per share.
- Expected Net Proceeds: Approximately $75 million (after underwriting discounts, commissions, and estimated offering expenses).
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to 750,000 additional shares at $15.04 per share.
Note: The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity as this is a transactional report, not a periodic financial statement.
Material Changes
The primary material change is the execution of an underwriting agreement with Jefferies LLC and Piper Jaffray & Co. as representatives. This agreement facilitates the issuance of new equity, which will increase the company's cash position upon closing. The offering is expected to close on or about October 31, 2016, subject to customary closing conditions.
Guidance, Outlook, and Risks
Management Commentary: The company issued a press release on October 26, 2016, announcing the pricing of the offering. The offering is made pursuant to an effective registration statement on Form S-3 declared effective on October 18, 2016.
Risks and Contingencies:
- The closing of the offering is subject to customary conditions set forth in the Underwriting Agreement.
- Investors are advised that representations and warranties in the Underwriting Agreement are solely for the benefit of the parties to the agreement and should not be relied upon as characterizations of the actual state of facts or conditions of Collegium.
Important Facts for Investors to Verify
- Confirmation of the closing date (expected October 31, 2016) and final net proceeds received.
- Whether the underwriters exercise the option to purchase the 750,000 additional shares.
- The specific allocation of the approximately $75 million in net proceeds as disclosed in subsequent filings.
- Review of the full Underwriting Agreement (Exhibit 1.1) for specific covenants and termination provisions.